Literature DB >> 2261148

Elevated insulin, norepinephrine, and neuropeptide Y in hypertension.

V B Solt1, M R Brown, B Kennedy, O G Kolterman, M G Ziegler.   

Abstract

To investigate the relationship between insulin and sympathetic activity, plasma norepinephrine, neuropeptide Y, serum glucose and insulin concentrations were measured in ten age-, weight-, and sex-matched normotensive and untreated hypertensive subjects at fasting and 2 h following ingestion of a 75 g oral glucose dose. Hypertensives had higher fasting serum insulin (27 +/- 6 v 12 +/- 2 microU/mL; P = .02) and plasma norepinephrine (356 +/- 38 v 235 +/- 35 pg/mL; P = .03) concentrations than normotensives. Glucose load increased serum insulin (P less than .001) and plasma norepinephrine concentrations (P = .001) in both groups and hypertensives had still higher postglucose insulin (P = .003) and norepinephrine levels (P = .003) than normotensives. Fasting neuropeptide Y was higher in hypertensives than in normotensives (P = .03) and correlated with age in both groups (r = 0.7; r = 0.77). Postglucose serum insulin correlated positively with plasma norepinephrine (r = 0.75; P = .013) in normotensives, but these parameters correlated negatively in hypertensives (r = -0.7; P = .036). We hypothesize that elevated plasma norepinephrine and neuropeptide Y levels reflect an increased level of sympathetic nervous activity in hypertensives, which in turn may be responsible for the abnormal relationship between plasma NE and insulin levels.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2261148     DOI: 10.1093/ajh/3.11.823

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  8 in total

1.  Changes in plasma catecholamine and neuropeptide Y levels after sympathetic activation in dogs.

Authors:  M F Poncet; C Damase-Michel; G Tavernier; M A Tran; M Berlan; J L Montastruc; P Montastruc
Journal:  Br J Pharmacol       Date:  1992-01       Impact factor: 8.739

2.  Attenuation of contractile responses to sympathetic co-transmitters in veins from subjects with essential hypertension.

Authors:  H Lind; D Erilnge; J Brunkwall; L Edvinsson
Journal:  Clin Auton Res       Date:  1997-04       Impact factor: 4.435

3.  Elevated levels of neuropeptide Y in preeclampsia: A pilot study implicating a role for stress in pathogenesis of the disease.

Authors:  Sara P C Paiva; Clara A Veloso; Fernanda F C Campos; Márcia M Carneiro; Jason U Tilan; Hongkun Wang; Jason G Umans; Zofia Zukowska; Joanna Kitlinska
Journal:  Neuropeptides       Date:  2015-09-25       Impact factor: 3.286

4.  Is neuropeptide Y co-released with catecholamines in experimental arterial hypertension following sinoaortic denervation?

Authors:  G Tavernier; C Damase-Michel; G Portolan; M A Tran; J L Montastruc
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-04       Impact factor: 3.000

5.  Inhibitory effects of angiotensin-(1-7) on the nerve stimulation-induced release of norepinephrine and neuropeptide Y from the mesenteric arterial bed.

Authors:  Mirnela Byku; Heather Macarthur; Thomas C Westfall
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-11-20       Impact factor: 4.733

Review 6.  Adverse metabolic effects of antihypertensive drugs. Implications for treatment.

Authors:  H G Preuss; J F Burris
Journal:  Drug Saf       Date:  1996-06       Impact factor: 5.606

Review 7.  Pathogenesis of the essential hypertensions.

Authors:  J G Mongeau
Journal:  Pediatr Nephrol       Date:  1991-07       Impact factor: 3.714

8.  Modulation of vascular function by neuropeptide Y during development of hypertension in spontaneously hypertensive rats.

Authors:  Z Zukowska-Grojec; M Golczynska; G H Shen; A Torres-Duarte; M Haass; C Wahlestedt; A K Myers
Journal:  Pediatr Nephrol       Date:  1993-12       Impact factor: 3.714

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.